anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Flecainide acetate has been administered to patients receiving digitalis preparations or beta-adrenergic blocking agents without adverse effects. During administration of multiple oral doses of flecainide acetate to healthy subjects stabilized on a maintenance dose of digoxin, a 13% to 19% increase in plasma digoxin levels occurred at six hours postdose.

In a study involving healthy subjects receiving flecainide acetate and propranolol concurrently, plasma flecainide levels were increased about 20% and propranolol levels were increased about 30% compared to control values. In this formal interaction study, flecainide acetate and propranolol were each found to have negative inotropic effects; when the drugs were administered together, the effects were additive. The effects of concomitant administration of flecainide acetate and propranolol on the PR interval were less than additive. In flecainide acetate clinical trials, patients who were receiving beta blockers concurrently did not experience an increased incidence of side effects. Nevertheless, the possibility of additive negative inotropic effects of beta blockers and flecainide should be recognized.

Flecainide is not extensively bound to plasma proteins. In vitro studies with several drugs which may be administered concomitantly showed that the extent of flecainide binding to human plasma proteins is either unchanged or only slightly less. Consequently, interactions with other drugs which are highly protein bound (e.g., anticoagulants) would not be expected. Flecainide acetate has been used in a large number of patients receiving diuretics without apparent interaction. Limited data in patients receiving known enzyme inducers (phenytoin, phenobarbital, carbamazepine) indicate only a 30% increase in the rate of flecainide elimination. In healthy subjects receiving cimetidine (1 gm daily) for one week, plasma flecainide levels increased by about 30% and half-life increased by about 10%.

When amiodarone is added to flecainide therapy, plasma flecainide levels may increase two-fold or more in some patients, if flecainide dosage is not reduced. (See DOSAGE AND ADMINISTRATION).

Drugs that inhibit cytochrome P450IID6, such as quinidine, might increase the plasma concentrations of flecainide in patients that are on chronic flecainide therapy; especially if these patients are extensive metabolizers.

There has been little experience with the coadministration of flecainide acetate and either disopyramide or verapamil. Because both of these drugs have negative inotropic properties and the effects of coadministration with flecainide acetate are unknown, neither disopyramide nor verapamil should be administered concurrently with flecainide unless, in the judgment of the physician, the benefits of this combination outweigh the risks. There has been too little experience with the coadministration of flecainide acetate with nifedipine or diltiazem to recommend concomitant use.
Fiberoptic bronchoscopy (FOB) is widely used in intensive care units as a diagnostic or therapeutic procedure. FOB in respiratory failure patients supported by mechanical ventilation may worsen hypoxemia and hypercapnia, therefore FOB requires careful consideration in this patient population. The generally accepted indications for FOB in ventilated patients are removal of retained secretions, resolution of atelectasis and evaluation of hemoptysis. A diagnostic indication is the bronchoalveolar lavage (BAL), to sample the lower respiratory tract without contamination. Studies of FOB performed in mechanically ventilated patients suggest an acceptable safety profile, except for the occurrence of hypoxemia as the main adverse event. Bronchoalveolar Lavage (BAL) in normal volunteers is reported to be safe and does not lead to measurable changes in pulmonary function parameters. However, in intensive care patients may suffer from serious side effects such as prolonged oxygen desaturation. Moreover, reductions in arterial oxygen tension (PaO2) have been reported to persist in some patients for 4 h and more after the procedure. Authors reported the BAL procedure is associated to a worsening of PaO2/FiO2 ratio, in several ARDS patients the drop in PaO2 was higher than 30%. Moreover a physiological study in patients undergoing FOB and BAL showed adverse change in lung compliance and resistance.

The purpose of this prospective study is to determine the alterations in respiratory mechanics (regional compliance and resistance) and gas exchange induced by FOB and BAL up to 6 hours after the procedure. The lung regional ventilation evaluation will be made by electrical impedance tomography (EIT).
PURPOSE: A siRNA having an effect of treating atopic dermatitis is provided to suppress CCL17 gene and IL-4 expression and to enhance IFN-gamma expression. CONSTITUTION: A therapeutic agent for treating atopic dermatitis contains bacteria cells as an active ingredient, which are transformed by a recombinant vector containing a gene which induces transcription of siRNA. The bacteria cells are Salmonella typhimurium BRD509. The siRNA has a base sequence of sequence number 2. The recombinant vector is pcDNA-CCL17miRNA. The therapeutic agent is manufactured in the form of powder, granule, tablet, capsule, or injection.
FIELD: medicine, neurology, phytotherapy, pharmacy. SUBSTANCE: invention relates to the development of agents used in treatment of nervous diseases. Invention proposes agent for treatment of epilepsy and convulsive syndrome comprising water-soluble chitosan, dry extract of medicinal plants and vehicle taken in the ratio 1:15:4, respectively. Dry extract comprises motherwort quinquelobate herb, valerian officinal rhizomes, common wormwood herb, Saint-John's-wort perforated herb, melissa officinal herb, haw-thorn blood-red flowers, marjoram officinal herb and oats in stage of milky-wax ripeness taken in the ratio = 2:2:1:1:2:2:1:4, respectively. Agent can be prepared as 0.5 g tablet and prescribed for oral intake in the dose 1 tablet, 3 times per a day, 15 min before eating for 4-26 weeks. Intake of this agent provides stable therapeutic effect and prolongs intra-attack period disease. EFFECT: valuable medicinal properties of agent. 3 cl, 3 ex
Lung bronchoalveolar carcinoma (BAC) or adenocarcinoma in situ (AIS) continues to represent a poorly understood clinical entity. A frequent clinical dilemma in lung cancer care is the management of a documented or suspected invasive adenocarcinoma in the setting of multifocal ground glass opacity (GGO) consistent with multifocal AIS. These patients are typically classified as stage IV disease, and treated with palliative chemotherapy. No existing pathologic or molecular test is currently capable of making the distinction between independent primary versus metastatic tumors, a distinction for which substantial treatment impact exists. Many treating physicians suspect that outcomes for this specific patient subgroup are better than norms for stage IV disease, as such patients are frequently node-negative and without distant metastases despite multiple lesions present. To address this issue, we will evaluate a multimodality treatment protocol using aggressive local and targeted systemic therapy for multifocal lung adenocarcinoma, incorporating information from tumor genome sequencing for individualized treatment planning. The results will have significant impact in advancing the biologic understanding and treatment approach for lung adenocarcinoma in the setting of multifocal AIS.
PURPOSE:To obtain a remedy for acne keeping high adhesivity to the skin even after drying and having high sebum absorptivity, by compounding aluminum magnesium silicate with precipitated silica fine powder at a specific ratio and adding a nonionic surfactant and water to the mixture. CONSTITUTION:The remedy for acne is composed of 2.0-20.0pts.wt. of aluminum magnesium silicate, 0.2-9.0pts.wt. of precipitated silica fine powder, 0.1-8.0 pts.wt. of a nonionic surfactant and 63.0-93.6pts.wt. of water wherein the weight ratio of aluminum magnesium silicate to precipitated silica fine powder is 15:1-15, preferably 7:1-7. The particle diameter of the precipitated silica fine powder is preferably <=100mmu. The adhesivity of the composition to the skin can be maintained even after drying and the sebum absorptivity is improved to improve the remedying effect of acne by the combined use of aluminum magnesium silicate and precipitated silica fine powder.
Image Guided, Stereotactic Body Radiotherapy (27 Gy over 3 fractions) to 1-3 lesions. Treatment with the checkpoint inhibitor will continue until progression at the discretion of the treating physician or unacceptable toxicity.
PROBLEM TO BE SOLVED: To obtain an oral tablet capable of increasing compliance to patients and contributing to quality of life by including ibudilast as an active ingredient and sustainedly releasing ibudilast by a specific method. SOLUTION: This oral tablet contains ibudilast represented by the formula as an active ingredient and precisely controls the eluting property. The control of eluting property is carried out by subjecting, e.g. uniform mixture of ibudilast with an enteric polymer (e.g. cellulosic polymer or an acrylic polymer), a sustained release agent (e.g. a water-soluble polymer or waxes) and additive for tablets to compression molding. The sustained release oral tablet is further preferably coated with a coating agent (e.g. hydroxymethyl cellulose or hydroxypropyl methyl cellulose). Adverse effect such as nausea or vomiting action after oral administration can be suppressed by carrying out the treatment.
The invention discloses a yin-nourishing Chinese medicinal composition for treating diarrhea. The Chinese medicinal composition consists of the following Chinese medicinal raw materials in parts by weight: 3-10 parts of straight ladybell root, 2-7 parts of sealwort, 2-8 parts of dendrobium, 1-10 parts of fragrant solomonseal rhizome, 1-5 parts of dark plum fruit, 1-5 parts of radix paeoniae alba, 1-5 parts of gorgon euryale seed, 2-7 parts of Chinese magnoliavine fruit, 10-20 parts of Lilium brownii, 1-5 parts of fructus mume, 5-15 parts of rosa rugosa, 3-10 parts of fructus citri sarcodactyli, 1-5 parts of flower of official magnolia and 1-5 parts of loquat leaf. The Chinese medicinal composition is compounded from finely-selected medicinal materials under the guidance of the traditional theory of traditional Chinese medicine and clinical experience. All the components of the composition are natural Chinese medicinal raw materials most of which have the effects of nourishing yin and tonifying kidney. The composition is easy and convenient to prepare, is wide in material source, is low in cost, and follows the prescription medication principle of the traditional Chinese medicine. Various composition medicinal materials are taken after being decocted in water. As proved by clinical application, the Chinese medicinal composition has a remarkable curative effect, reliable action and mild medicinal property, is free from toxic and side effects, is 77.42 percent in healing rate, and is 93.55 percent in total effective rate.
The present invention relates to the field of preparing Chinese medicine dosage form and relates specifically to a Salvia miltiorrhiza Bge. wall-breaking dosage form. The present invention pulverizes Salvia miltiorrhiza Bge. into wall-broken powder, which is subjected to an alcohol-water wetting process to be granulated, extrusion formed under a predetermined rotational speed and then dried. The Salvia miltiorrhiza Bge. wall-breaking dosage form so manufactured has an increased bioavailability and the dosage form has improved stability and good disintegrability. The method comprises the following steps: (1) performing ultrafine pulverization to Salvia miltiorrhiza Bge. to obtain ultrafine powder; (2) adding alcohol-water solution formed of alcohol having quality fraction of 40-99% to the ultrafine powder to form a soft material, the weight ration of the ultrafine powder and the alcohol-water solution being 1:0.3-0.8; and (3) extruding the soft material to form wet granules and drying the wet granules to form the Salvia miltiorrhiza Bge. dosage form.
The gravitas are informed about spontaneous pushing at the active phase of dilatation (6cm) in second stage of labour and they are encouraged for spontaneous pushing just at the onset of pushing. At the expulsion phase (baby's head is visible in vulva), they are encouraged to perform the Valsalva's manoeuvre that they have practised in routines of delivery; When contractions start, breathe twice normally. Take a deep breath and hold. Compress the air with the help of diaphragm and abdominal muscles. Push strongly and long (for 10-15 sec). Breathe out and take another deep breath, hold it and push as strongly as possible for another 10-15 seconds. Stop pushing when contractions are mild. Breathe 2-3 times in normal style. Relax and have a rest until the next contraction.
A roller stir-frying machine door device relates to a door device for a roller stir-frying machine, a roller drying machine and others. The roller stir-frying machine door device comprises a door shaft seat and a door shaft arranged on the door shaft seat. The door shaft is provided with a beam on which a transverse rotating shaft, feeding door component, a discharging door component, a locating component and a door buckle are arranged. The transverse rotating shaft is fixed at the outer side of the beam through a rotating shaft seat. The feeding door component is fixedly connected with a feeding door bushing arranged on the transverse rotating shaft through an upper connecting pipe. The discharging component is fixedly connected with a left bushing and a right bushing, which are arranged on the transverse rotating shaft through a lower connecting pipe. The utility model has the beneficial effects that the utility model positions the closing and the starting of a feeding door and a discharging door through a positioning hole, the beam can rotate around the door shaft, the whole door can be opened or closed and the operation is convenient and quick.
Patients were randomly assigned in to three groups of 50 each using a computer-generated table of random numbers. Patients Group D25 were injected intravenously with 0.25mic/kg of dexmedetomidine diluted with normal saline into 10ml before injection of propofol.
PURPOSE:To obtain agar-agar soluble at lower temperatures, suitable in such fields as foods, drugs and biotechnology, by cooling an agar-agar solution of specified temperature to another specified temperature to effect freezing and then thawing followed by dehydration. CONSTITUTION:A commercial agar-agar is dispersed in water followed by warming to prepare an agar-agar solution of a temperature high than the coagulating point of said agar-agar by >=15 deg.C (pref. by >=20 deg.C). Thence, this solution is cooled to a temperature of <=0 deg.C within 5(pref. 2)min to effect freezing. The resultant frozen solution is left to stand at 5-50 deg.C for 0.5-24hr to effect thawing followed by dehydration and drying, thus obtaining the objective agar-agar. Said thawing is preferably performed by dipping the frozen solution in water at 5-50 deg.C for 0.5-24hr.
The invention relates to intelligent editing of image processing results. A computer-implemented method for editing image processing results includes performing one or more image processing tasks on an input image using an iterative editing process. The iterative editing process is performed until a user exit request is received. Each iteration of the iterative editing process includes generating a plurality of processed images using a first machine learning model. Each processed image corresponds to a different set of processing parameters. The iterative editing process further includes presenting the plurality of processed images to a user on a display and receiving a user response including (i) indicating acceptance of one or more of the processed images, (ii) indicating rejection of all of the processed images, or (iii) a user exit request. Following an iterative editing process, a clinical task is performed by using at least one of the processed images generated immediately prior to receiving the user exit request.
PROBLEM TO BE SOLVED: To produce a new compound, having an excellent solubility, good stability even under weak acidic conditions, antimicrobial effects and useful as a cosmetic, a pharmaceutical preparation, an agricultural formulation, an animal drug formulation, a food, a feed, etc. SOLUTION: This zinc salt of L-ascorbic acid 2-phosphate and its hydrate salt. The compound is obtained by carrying out a chemical reaction of, e.g. a salt other than zinc of L-ascorbic acid 2-phosphate (e.g. Ap2 Mg3 when the L-ascorbic acid 2-phosphate is represented by Ap) as a raw material with an element such as Mg or substituting the element with zinc element by ion exchange, etc. The reaction can be combined with a purifying method. In the zinc salt of the L-ascorbic acid 2-phosphate and its hydrate salt, >=95% based on the total charges of cations are preferably derived from zinc and >=95% based on the total charges of anions are preferably derived from L-ascorbic acid 2-phosphate.
Biopsies will be obtained by flexible autoclavable cryoprobe 20416-032 (Erbokryo CA, ERBE, Germany) with 2.4 mm in diameter. The tip of the probe is cooled to -890C with nitrous oxide within seconds after footswitch activation. The biopsy sample will by extracted by gently pulling of the probe.
Physicians should individualize treatment using a progressive plan of pain management such as outlined by the World Health Organization, the American Pain Society and the Federation of State Medical Boards Model Guidelines. Healthcare professionals should follow appropriate pain management principles of careful assessment and ongoing monitoring. AVINZA (morphine sulfate) is on the third step of the WHO three step analgesic ladder and is of most benefit when a constant level of opioid analgesia is used as a platform from which break-through pain is managed. Once acceptable pain relief is no longer achieved from combinations of non-opioid medications (NSAIDs and acetaminophen) and intermittent usage of moderate or strong opioids, conversion to a 24-hour oral morphine equivalent is warranted.

The dose may be titrated as frequently as every other day to control analgesia. In the event that break-through pain occurs, AVINZA may be supplemented with a small dose (5-15% of the total daily dose of morphine) of a short-acting analgesic. 

When AVINZA is chosen as the initial opioid for patients who do not have a proven tolerance to opioids, patients should be treated initially at a dose of 30 mg once-daily (at 24-hour intervals). For opioid-naïve patients, the dose should be increased conservatively. For such patients, it is recommended that the dose of AVINZA be adjusted in increments not greater than 30 mg every 4 days. Some degree of tolerance may occur, requiring dosage adjustment until the achievement of a balance between analgesia and opioid side effects. When necessary, the total dose of AVINZA should be increased until pain relief is reached or clinically significant opioid-related adverse reactions occur.
Those randomized to this group will undergo systematic chemotherapy and radiation. In brief, participants will receive 33-36 daily fractions of radiation therapy 5 days a week. Concurrently, radiosensitizing chemotherapy involves either cisplatin plus 5-fluorouracil (5-FU) or mitomycin C (MMC) plus 5-FU. Other concurrent chemotherapy regimens utilized include paclitaxel and gemcitabine. The decision for specific chemotherapy regimen is based on numerous variables such as participant's comorbidities, GFR, participant's preference, availability of chemotherapeutic regimen.
Boswellia serrata produces oleo gum resin, a rich source of essential oil (EO). EOs, produced as secondary metabolites by medicinal plants, are employed for medicinal and therapeutic purposes. The present study aimed to investigate the yield, chemical composition, antioxidant (AO), antimicrobial, and hemolytic activity of B. serrata EO and its fractions and sub-fractions (SFs). The EO was extracted using the superheated steam extraction (SHSE) method at 140°C. Short-path molecular vacuum distillation was used to separate the EO into fractions and SFs. Gas chromatography-mass spectrometry analysis showed α-pinene, α-thujene, trans verbenol, and linalool as major components of EO. The AO potential was evaluated using a 2,2-diphenyl-1-picrylhydrazyl assay, % inhibition in a linoleic acid assay, H2O2 scavenging assay, and total AO content (TAOC) using a ferric reducing AO power assay. F2b SF exhibited the highest scavenging activity, with percentages of 95.77%, 96.20%, and 83.54%, respectively, whereas EO revealed the highest TAOC value of 115.94%. Antimicrobial activity was evaluated by disc diffusion, resazurin microtiter plate, and microdilution broth assays. F1c SF showed maximum antibacterial potential (high inhibition zone 17.65-38.28 mm and low minimum inhibitory concentration [MIC] 2.20-84.44 µg/mL). The EO showed the highest antifungal activity (high inhibition zone 12.58-25.81 mm and low MIC 35.18-225.17 µg/mL). Cytotoxicity was assessed by hemolytic assay, with the F1c SF showing the highest activity at 10.89%. It is concluded that SHSE is an effective technique for B. serrata EO extraction, and this EO can be utilized for various medicinal purposes.
FIELD: medicine, veterinary science. ^ SUBSTANCE: invention relates to veterinary science. A method involves parenteral introduction of enrofloxacin to an affected animal. Enrofloxacin is dosed twice at most, and administered once a day for two following days in an amount 1 to 10 mg/kg a day. ^ EFFECT: method allows to simplify treatment of mastitis and provides higher clinical effectiveness. ^ 11 ex
Fifty healthy subjects (male: 22, female: 28) were offered a standardized breakfast and 2h after consumed one of the two preloads (carob snack and chocolate cookie) served as snack in random order. Three hours after, subjects were given ad libitum access to a meal (lunch and dessert). Foods were weighed at the time of serving and any leftovers were weighed again after meal to determine the amount of food consumed. Fingertip capillary blood glucose samples were collected before and after foods. Subjective appetite ratings were collected using 100mm visual analogue scales (VAS).
In acid sphingomyelinase knockout (ASMKO) mice (a disease model of ASMD), mortality was observed after a single dose ≥10 mg/kg administered as an IV bolus injection. Observations (lethargy, coolness to touch, and unwillingness to move), combined with the adrenal hemorrhage, suggested that hypotensive shock may be the cause of death. These findings were accompanied by necrosis and apoptosis in the liver and adrenal gland, elevations of ceramide, sphingosine and sphingosine 1-phosphate in the serum, catabolites of accumulated sphingomyelin as well as elevations in the serum concentrations of inflammatory mediators, such as cytokines and acute phase proteins.

In ASMKO mice, a dose-dependent reduction in heart rate accompanied by a decrease in motor activity and followed by a slow decline in blood pressure was noted after a single IV administration at 3, 10, and 20 mg/kg. After 2 doses of olipudase alfa-rpcp at 3 and 10 mg/kg to ASMKO mice, a slight decline in heart rate was noted following the second administration.

Repeated dose studies in adult ASMKO mice show that administration of olipudase alfa-rpcp via a dose escalation regimen, (3 mg/kg administered IV every other day, followed by a single IV dose of 20 mg/kg 3 days later) did not result in toxicity. The lack of adverse findings in BALB/c, C57BL/6 mice, rats, dogs, and monkeys at comparable olipudase alfa-rpcp doses suggested that the dose-related toxicity observed in ASMKO mice may be due to the rate and amount of substrate degradation.